Week 13-16: Your Penultimate Dose Before Maintenance
Why Choose Online Prescription for 1.7mg Wegovy?
Online prescription services have revolutionised access to 1.7mg Wegovy, eliminating the traditional barriers of GP availability and referral delays. Our 3-minute clinical assessment covers your medical history, current BMI, contraindications, and treatment progression, ensuring comprehensive evaluation without lengthy appointment scheduling. Licensed UK prescribers review every 1.7mg Wegovy application individually, maintaining the same clinical standards as traditional face-to-face consultations whilst providing significantly faster turnaround times.
The online prescription process for 1.7mg Wegovy removes geographical limitations and scheduling conflicts that often disrupt consistent treatment. Patients can complete their assessment 24/7, with prescriber reviews occurring within standard 3 working days or express 24-hour timelines. This reliability becomes particularly crucial at the 1.7mg dose stage, where treatment momentum and consistent supply directly impact your approaching transition to 2.4mg maintenance dosing.
1.7mg Wegovy Pricing and Bundle Options
Single 1.7mg Wegovy pens are priced at £139.99, representing the final cost after applying our DOSE25 discount code for returning customers at checkout. New customers benefit from the FIRST40 discount code, ensuring competitive pricing across all patient demographics. Our pricing structure reflects the increased semaglutide concentration required at this penultimate dose level, balancing affordability with the clinical requirements of weeks 13-16 treatment.
The Elevate Duo bundle combines 1.7mg and 2.4mg Wegovy for £369.99, providing seamless transition planning from your current dose to maintenance therapy. This bundle eliminates separate ordering requirements and ensures continuous supply chain management. The Consistency 1.7mg bundle offers two identical pens for £309.99, suitable for patients requiring extended time at this dose level before progressing to maintenance.
Clinical Evidence Supporting 1.7mg Wegovy Efficacy
The STEP clinical trial programme demonstrated progressive weight management benefits as patients advance through dose escalation, with 1.7mg representing a crucial stepping stone towards optimal therapeutic outcomes. In clinical trials, patients taking Wegovy alongside diet and exercise achieved significant weight reduction, with the 1.7mg dose contributing to the overall ~15% average weight loss observed at 68 weeks in STEP 1. The Wilding et al., NEJM, 2021 publication established the evidence base for this systematic dose escalation approach.
Clinical data indicates that patients who maintain consistent progression through the 1.7mg Wegovy phase show improved tolerance and efficacy when transitioning to 2.4mg maintenance dosing. The dose escalation protocol, including the 1.7mg phase, was specifically designed to optimise gastrointestinal adaptation whilst building therapeutic semaglutide levels. This systematic approach supports the ~clinically studied weight loss achieved in STEP 3 when combined with intensive behavioural therapy.
How 1.7mg Wegovy Works in Your Body
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone, providing enhanced appetite regulation at the 1.7mg concentration. This dose activates GLP-1 receptors in your brain's appetite centres, promoting satiety after smaller meals and potentially reducing food cravings between eating occasions. The 1.7mg strength represents 85% of the full maintenance dose, delivering substantial therapeutic benefit whilst preparing your system for the final escalation. Semaglutide at this concentration slows gastric emptying, contributing to prolonged feelings of fullness that support adherence to reduced-calorie diet requirements. The once-weekly injection schedule maintains consistent semaglutide levels, supporting stable appetite suppression throughout your treatment week. This mechanism, combined with increased physical activity, creates the foundation for sustainable weight management as you approach maintenance therapy.
Ordering Your 1.7mg Wegovy Prescription Online
The online ordering process begins with our comprehensive 3-minute clinical assessment, covering your weight management history, current medications, allergies, and progression through previous Wegovy doses. Licensed UK prescribers evaluate each 1.7mg Wegovy application against MHRA guidelines and NICE TA875 recommendations, ensuring clinical appropriateness before prescription approval. Standard prescriber review occurs within 3 working days, with express 24-hour processing available for urgent supply requirements. Upon prescription approval, your 1.7mg Wegovy ships via next-day delivery using temperature-controlled cold-chain logistics, maintaining the 2-8°C storage requirements throughout transit. Order confirmation includes detailed administration guidance, storage instructions, and progression planning for your upcoming 2.4mg transition. All prescriptions originate from our GPhC #9012878 registered pharmacy, ensuring full regulatory compliance and patient safety standards.
Storage and Administration of 1.7mg Wegovy
Store your 1.7mg Wegovy pen in the refrigerator at 2-8°C before first use, with the flexibility of 6 weeks room temperature storage below 30°C once removed from refrigeration. The FlexTouch pen design ensures accurate 1.7mg dose delivery through its pre-filled, single-use format that eliminates dosing errors. Administer your weekly injection on the same day each week, rotating between thigh, abdomen, or upper arm injection sites to prevent lipodystrophy. The 1.7mg dose represents week 13-16 of your escalation schedule, requiring consistent timing to maintain therapeutic semaglutide levels before progressing to 2.4mg maintenance. Keep your pen cap on when not in use and never freeze or shake the medication, as this can compromise the semaglutide formulation. The 6-week room temperature stability provides significant advantage over alternative treatments, supporting travel flexibility and reducing storage anxiety.
Transitioning Through 1.7mg Wegovy: Your Penultimate Step
The 1.7mg Wegovy dose occupies a unique position in your weight management journey, representing the final preparation phase before reaching full maintenance therapy. Patients at this stage often experience accelerated results as therapeutic semaglutide levels approach optimal concentrations, making consistent online prescription access crucial for maintaining treatment momentum. The online prescription model eliminates potential supply disruptions that could compromise your progression to 2.4mg maintenance dosing.
Planning your 1.7mg to 2.4mg transition requires strategic ordering to prevent treatment gaps that could necessitate dose re-escalation. Our Elevate Duo bundle specifically addresses this transition period, providing both your current 1.7mg dose and subsequent 2.4mg maintenance in a single order. Online prescribing enables proactive transition planning, ensuring seamless progression without the appointment scheduling delays that often complicate traditional prescription pathways.
Secure Your 1.7mg Wegovy Prescription Today
Complete your clinical assessment now to maintain treatment continuity at this crucial penultimate dose stage. New customers apply FIRST40 at checkout, whilst returning customers use DOSE25 to secure the £139.99 pricing for single pens, or consider the Elevate Duo at £369.99 for transition planning. Your prescription-only medicine ships next-day upon approval, maintaining the cold-chain integrity essential for semaglutide stability. Our licensed prescribers provide expert evaluation within 3 working days, ensuring clinical safety whilst minimising supply delays. Visit https://everydaymeds.co.uk/products/wegovy-1-7mg to begin your assessment and continue your weight management journey with confidence. Trust in our GPhC #9012878 registered pharmacy service for reliable, professional care throughout your Wegovy treatment pathway.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
